Targets individual therapeutics

Little evidence exists for most individuals that moderately limiting oxygen causes long-term health defects. Thus, the points at which oxygen availability is sensed by the HIE system (i.e., the HIE hydroxylases) are arguably preferred targets for therapeutic intervention. Very good precedent was set for... 

Identifies therapeutic categories or individual therapeutic agents warranting drug utilization evaluation. Develops and conducts drug utilization evaluation in these targeted areas. 

The exact role of individual histone acetylations will have to be determined in the context of other modifications and the number of lysine residues effected. However, the general importance of histone acetylation as a regulator for chromatin activity is undisputed. This leads to the intriguing possibility to develop drugs that target histone acetylation for therapeutic purposes. The primary targets for drug development are the histone acetyl transferases (HATs) and the histone deacetylases (HDACs) which introduce and remove histone acetylations [2, 3]. 

The development of ligands selective for individual receptor subtypes relevant to a targeted disease could decrease these toxic effects thereby improving the therapeutic index. Two new arotinoids are already available for topical use in skin diseases. These are tazarotenic acid (tazarotene) and 6-[3-(l-adamanty 1)-... 

---